Drug Profile


Alternative Names: INO-8875; PJ-875

Latest Information Update: 05 Jan 2017

Price : $50

At a glance

  • Originator Inotek Pharmaceuticals
  • Class Antiarrhythmics
  • Mechanism of Action Adenosine A1 receptor agonists; Gelatinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Glaucoma; Ocular hypertension
  • Preclinical Optic nerve disorders
  • Discontinued Arrhythmias; Atrial fibrillation; Pain

Most Recent Events

  • 03 Jan 2017 Top-line results from phase III MATrX-1 trial released by Inotek
  • 01 Nov 2016 Inotek Pharmaceuticals completes the MATrX-1 trial in Glaucoma and Ocular hypertension in USA (Ophthalmic) (NCT02565173)
  • 24 Aug 2016 Inotek Pharmaceuticals completes enrolment in its phase III trial for Glaucoma and Ocular hypertension
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top